Dou et al. described immunohistochemistry (IHC)-confirmed early-stage lung cancer with an intergenic-breakpoint ALK fusion based on previous studies which described worse postoperative outcomes in patients with ALK rearrangement early-stage NSCLC; adequate treatment should be provided to reduce postoperative recurrence [22]. This evidence concerns the gene ALK and lung cancer.